Clinical Trials Logo

Rhinitis clinical trials

View clinical trials related to Rhinitis.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05908032 Active, not recruiting - Allergic Rhinitis Clinical Trials

Study of CM310 in Subjects With Allergic Rhinitis

PHECDA
Start date: August 10, 2023
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study aimed at evaluating the efficacy and safety of CM310 in patients with seasonal allergic rhinitis, and observing the quality of life, PK, PD characteristics, and immunogenicity of subjects.

NCT ID: NCT05591989 Active, not recruiting - Chronic Rhinitis Clinical Trials

Clinical Evaluation of Safety and Efficacy for the NEUROMARK System in Subjects With Chronic Rhinitis (PARAGON)

Start date: September 26, 2022
Phase: N/A
Study type: Interventional

The PARAGON Study is a prospective, single-arm, multicenter safety and efficacy study of the Neurent Medical NEUROMARK System in subjects with chronic rhinitis.

NCT ID: NCT05476484 Active, not recruiting - Asthma Clinical Trials

Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and Asthma

Start date: April 1, 2022
Phase:
Study type: Observational

To assess the impact of SQ SLIT-tablets (SQ Grass SLIT-tablet and SQ HDM SLIT-tablet) in Danish and Swedish allergic rhinitis (AR) patients, with or without asthma, between 2007-2020.

NCT ID: NCT05297760 Active, not recruiting - Allergic Rhinitis Clinical Trials

Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract

Start date: February 10, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The primary goal is to investigate the efficacy of intralymphatic immunotherapy (ILIT) for the treatment of allergic rhinitis and allergic asthma due to sensitisation to grass pollen allergens. 60 patients with allergic rhinitis will be included and randomized to receive either Polvac (n=30) or placebo (n=30). All patients will receive three injections with 4-8 weeks interval. The injections into a inguinal lymph node is guided by sonography. Patients will record symptoms and medication use in the summer of 2022 and 2023.

NCT ID: NCT05286944 Active, not recruiting - Rhinitis, Allergic Clinical Trials

Mobile Phone Daily Alarm To Improve Compliance Of Intranasal Corticosteroid Among Allergic Rhinitis Patients.

Start date: January 19, 2020
Phase: N/A
Study type: Interventional

This is a randomized controlled trial to compare the compliance of allergic rhinitis patients towards intranasal steroids between those who use mobile daily alarm reminder and those who do not.

NCT ID: NCT05191186 Active, not recruiting - Allergic Asthma Clinical Trials

Documentation of Efficacy of Intralymphatic Allergen Immunotherapy

ILITNU
Start date: February 1, 2020
Phase: Phase 3
Study type: Interventional

Investigation of the clinical efficacy of 3 intralymphatic injections with grass pollen extract into inguinal lymph nodes on combined symptom-medication scores during grass pollen season in grass pollen allergic patients compared to placebo

NCT ID: NCT05186025 Active, not recruiting - Clinical trials for Allergic Conjunctivitis

Tyrosine Allergoid Paediatric and Adult Study

Start date: November 6, 2020
Phase:
Study type: Observational

The primary objective of this 5-year study is to demonstrate non-inferiority of children compared to adults by exploring long-term effectiveness after treatment with TA Bäume (trees) and TA Gräser (grass) following a perennial posology.

NCT ID: NCT05038202 Active, not recruiting - Allergic Rhinitis Clinical Trials

Study of Bencycloquidium Bromide Nasal Spray in the Treatment of Moderate-severe Persistent Allergic Rhinitis

Start date: June 16, 2021
Phase: Phase 4
Study type: Interventional

450 subjects with moderate-severe persistent allergic rhinitis will be enrolled in the trial and divided into three groups for different treatments. Group A:Subjects with Bencycloquidium Bromide Nasal Spray, Group B:Subjects with Mometasone Furoate Aqueous Nasal Spray, Group C:Subjects with Bencycloquidium Bromide Nasal Spray in combination with Mometasone Furoate Aqueous Nasal Spray.The main purpose of the trial is to evaluate the efficacy of Bencycloquidium Bromide Nasal Spray alone or in combination with Mometasone Furoate Aqueous Nasal Spray in the treatment of moderate-severe persistent allergic rhinitis and rhinorrhea.

NCT ID: NCT04619017 Active, not recruiting - Allergic Rhinitis Clinical Trials

Airway Immune Response to Allergens (Use Lay Language Here)

Start date: October 28, 2021
Phase: Phase 1
Study type: Interventional

Most asthma is allergic in origin. The purpose of this study is to better understand the airway immune response to inhaled allergens in order to identify factors that promote asthma.

NCT ID: NCT04614324 Active, not recruiting - Chronic Rhinitis Clinical Trials

A Study of RhinAer ARC Stylus for Treating Chronic Rhinitis (RELIEF)

RELIEF
Start date: October 5, 2020
Phase: N/A
Study type: Interventional

Post-market study to continue to evaluate the effectiveness of the RhinAer ARC Stylus for chronic rhinitis.